Evaluation of renal function in patients with cirrhosis: Where are we now?

被引:30
|
作者
Rognant, Nicolas [1 ,2 ,3 ]
Lemoine, Sandrine [1 ,2 ]
机构
[1] Hosp Civils Lyon, Dept Nephrol, Lyon, France
[2] Univ Lyon 1, F-69008 Lyon, France
[3] Univ Bristol, Sch Biochem, Bristol BS8 1TD, Avon, England
关键词
Cirrhosis; Glomerular filtration rate; Formula; Estimation; Agreement; Plasma creatinine; Cystatin C; GLOMERULAR-FILTRATION-RATE; GELATINASE-ASSOCIATED LIPOCALIN; PLASMA CYSTATIN-C; SERUM CREATININE; LIVER-TRANSPLANTATION; MEDICAL PROGRESS; INULIN-CLEARANCE; DIAGNOSTIC-VALUE; KIDNEY-FUNCTION; DISEASE;
D O I
10.3748/wjg.v20.i10.2533
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the clinical context of the patients with liver cirrhosis, accurate evaluation of the renal function is potentially crucial. Indeed, it can lead to early diagnosis of both acute kidney injury and chronic kidney disease and to reliable characterization of the renal status of the patient before performing a liver transplantation. Despite some limitations, the assay of serum creatinine (SCr) is universally used to estimate glomerular filtration rate (GFR) because of its wide availability, its simplicity and because it is inexpensive. Nevertheless, several reports show that the value of this assay to estimate GFR is strongly challenged in cirrhotic patients, especially in patients with liver failure and/or severely impaired renal function. This has led to seek new alternatives to estimate more reliably the GFR in these patients. Although the reference methods, based on the utilization of exogenous markers, allow measuring GFR and thereby constitute the "gold standard" to evaluate renal function, they are not feasible in routine clinical practice. Several studies have shown that a cystatin C (CysC) based formula perform better than the SCr-based estimates in cirrhotic patients and the estimation of GFR by these formulas could therefore lead to optimize the management of the patients. A new estimate based on CysC has been recently developed using a large number of patients and the first results regarding the evaluation of its performance are promising, making this new formula the best candidate for a reference estimate of the renal function in cirrhotic patients. (C) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:2533 / 2541
页数:9
相关论文
共 50 条
  • [1] Evaluation of renal function in patients with cirrhosis:Where are we now?
    Nicolas Rognant
    Sandrine Lemoine
    World Journal of Gastroenterology, 2014, 20 (10) : 2533 - 2541
  • [2] Evaluation of renal function in patients with cirrhosis
    Cholongitas, Evangelos
    Xirouchakis, Elias
    Garcovich, Matteo
    Burroughs, Andrew K.
    JOURNAL OF HEPATOLOGY, 2010, 53 (03) : 589 - 589
  • [3] Renal dysfunction in patients with cirrhosis: Where do we stand?
    Chrysoula Pipili
    Evangelos Cholongitas
    World Journal of Gastrointestinal Pharmacology and Therapeutics, 2014, (03) : 156 - 168
  • [4] Proteomics for rejection diagnosis in renal transplant patients: Where are we now?
    Wilfried Gwinner
    Jochen Metzger
    Holger Husi
    David Marx
    World Journal of Transplantation, 2016, (01) : 28 - 41
  • [5] Biopsy of a renal mass: where are we now?
    Laguna, M. Pilar
    Kummerlin, Intan
    Rioja, Jorge
    de la Rosette, Jean J. M. C. H.
    CURRENT OPINION IN UROLOGY, 2009, 19 (05) : 447 - 453
  • [6] The evaluation of renal function and disease in patients with cirrhosis
    Francoz, Claire
    Glotz, Denis
    Moreau, Richard
    Durand, Francois
    JOURNAL OF HEPATOLOGY, 2010, 52 (04) : 605 - 613
  • [7] PITUITARY FUNCTION Acromegaly: where are we now?
    Katznelson, Laurence
    NATURE REVIEWS ENDOCRINOLOGY, 2009, 5 (08) : 420 - 422
  • [8] Newborn screening and renal disease: where we have been; where we are now; where we are going
    Merritt, J. Lawrence, II
    Askenazi, David
    Hahn, Si Houn
    PEDIATRIC NEPHROLOGY, 2012, 27 (09) : 1453 - 1464
  • [9] Newborn screening and renal disease: where we have been; where we are now; where we are going
    J. Lawrence Merritt
    David Askenazi
    Si Houn Hahn
    Pediatric Nephrology, 2012, 27 : 1453 - 1464
  • [10] Geriatric Drug Evaluation Where Are We Now and Where Should We Be in the Future?
    Cho, Seongeun
    Lau, S. W. Johnny
    Tandon, Veneeta
    Kumi, Kofi
    Pfuma, Elimika
    Abernethy, Darrell R.
    ARCHIVES OF INTERNAL MEDICINE, 2011, 171 (10) : 937 - 940